Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2012

01-06-2012 | Media release

Cangene recalls Hep B immune globulin due to thrombosis risk

Published in: Reactions Weekly | Issue 1/2012

Login to get access

Excerpt

A voluntary product recall of eight finished product lots of Hepatitis B immune globulin intravenous [HepaGam B], effective in Canada, the US and Israel, has been announced by Cangene Corporation. …
Literature
1.
Cangene Corporation.Cangene voluntarily recalls finished product from a single HepaGam B(Rm) manufacturing bulk lot. Media Release: 29 May 2012. Available from: URL: http://​www.​cangene.​com
Metadata
Title
Cangene recalls Hep B immune globulin due to thrombosis risk
Publication date
01-06-2012
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2012
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201214060-00006

Other articles of this Issue 1/2012

Reactions Weekly 1/2012 Go to the issue

Case report

Allergy immunotherapies

Case report

Rivastigmine

Case report

Doxorubicin liposomal

Case report

Natalizumab withdrawal

News item

TGA warns of candesartan risks in pregnancy

Case report

Influenza virus vaccine